Showing posts with label PI-103. Show all posts
Showing posts with label PI-103. Show all posts

Friday, August 24, 2012

Impartial Insider Report Exposes Some Un-Answered Questions On SNDX-275

This examine was accepted by the institutional assessment board or ethics committee from each of the participating PI3K Inhibitors web sites. All patients presented written informed consent prior to enrolment to the examine. An interactive voice response technique was utilised to randomly assign patients in a one:one ratio to fl udarabine plus alemtuzumab or fl udarabine monotherapy in an open label trial.